# Metabolic Surgery for Atrial Fibrillation Elimination

Study · id `cardio:ct-nct07027969` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07027969](<https://clinicaltrials.gov/study/NCT07027969>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07027969

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07027969. Randomized; no masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07027969, source copy `cardio:ctgov-nct07027969-2026-04-17`, retrieved 2026-10-26)
- Planned start: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT07027969, source copy `cardio:ctgov-nct07027969-2026-04-17`, retrieved 2026-10-26)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT07027969, source copy `cardio:ctgov-nct07027969-2026-04-17`, retrieved 2026-10-26)
- Completion: 2030-03-31 (anticipated) (ClinicalTrials.gov record NCT07027969, source copy `cardio:ctgov-nct07027969-2026-04-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07027969, source copy `cardio:ctgov-nct07027969-2026-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07027969-2026-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metabolic Surgery for Atrial Fibrillation Elimination
- Acronym: METSAFE
- Condition: Atrial Fibrillation
- Condition: Obesity and Obesity-related Medical Conditions
- Intervention (Procedure): Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- Intervention (Drug): Anti-Obesity Medication (AOM) treatment
- Lead sponsor: Ali Aminian
- Lead sponsor class: OTHER
- Collaborator: Ethicon, Inc.
- Collaborator class: INDUSTRY
- Collaborator: iRhythm Technologies, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as a collaborator: iRhythm Technologies, Inc. (`cardio:org-irhythm-technologies-inc`)

## Provenance

Content hash: 166635191a27e9e1422b893d156b14b8c5425127b80adb9f75a8a3bb7eb22edc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
